https://twitter.com/rahuja671/status/1735264585119113640
Novo Nordisk best-selling weight-loss drug Wegovy (semaglutide) made nearly $3.1 billion in revenue in the first 9 months of 2023. Novo’s other semaglutide product Ozempic, for diabetes, continued to be the company’s top asset. https://biospace.com/article/novo-logs-over-700-percent-wegovy-sales-growth-in-q3-raises-2023-outlook-/… #neulandlabs #semaglutide
https://twitter.com/rahuja671/status/1704483487581876346
Neuland is setting up a dedicated production block for one of its client Esperion for production of it’s New Chemical Entity (NCE), bempedoic acid which is major API in NEXLETOL and NEXLIZET a cholesterol lowering drug.
| Subscribe To Our Free Newsletter |
